Promising Developments and Consistent Performance Drive Buy Rating for Astria Therapeutics

H.C. Wainwright analyst Joseph Pantginis has reiterated their bullish stance on ATXS stock, giving a Buy rating on May 29.

Joseph Pantginis has given his Buy rating due to a combination of factors related to Astria Therapeutics’ promising developments. The company has showcased positive initial safety and efficacy results from the ALPHA-SOLAR long-term study of navenibart in patients with hereditary angioedema (HAE). These findings build upon the favorable treatment profile previously established in the Phase 1b/2 ALPHA-STAR study, indicating a consistent and potentially impactful therapeutic option.
Furthermore, the data from the ALPHA-SOLAR study highlight significant reductions in the monthly attack rate, including moderate and severe attacks, which are crucial for patient outcomes. The robust results support the ongoing global pivotal Phase 3 ALPHA-ORBIT trial, which is evaluating the drug’s administration every 3 and 6 months. This consistent performance and the potential market opportunity for navenibart underpin Pantginis’s confidence in recommending a Buy rating for Astria Therapeutics.

Pantginis covers the Healthcare sector, focusing on stocks such as Cytokinetics, Actinium Pharmaceuticals, and Kura Oncology. According to TipRanks, Pantginis has an average return of -17.3% and a 28.83% success rate on recommended stocks.

In another report released on May 29, Citizens JMP also reiterated a Buy rating on the stock with a $25.00 price target.